Dicerna Pharmaceuticals Obtains $60,000,000 Series C Funding

  • Feed Type
  • Date
    8/1/2013
  • Company Name
    Dicerna Pharmaceuticals
  • Mailing Address
    480 Arsenal Street Watertown, MA 02472
  • Company Description
    Dicerna Pharmaceuticals is a venture-backed startup developing novel therapeutics in multiple therapeutic areas based on Dicer substrate technology, which makes use of the RNA interference mechanism.
  • Website
    http://www.dicerna.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $60,000,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    Proceeds from the financing will be used to advance two or more programs into the clinic and to progress other preclinical programs. The company also plans to use the proceeds to continue to develop innovative drug delivery systems, which combine Dicerna’s DsiRNA molecules with targeting moieties allowing for direct delivery into specific cells of interest.
  • M&A Terms
  • Venture Investor
    RA Capital
  • Venture Investor
    Brookside Capital
  • Venture Investor
    Deerfield Capital
  • Venture Investor
    Omega Funds
  • Venture Investor
    Abingworth Management
  • Venture Investor
    Domain Associates
  • Venture Investor
    Oxford Bioscience Partners
  • Venture Investor
    Skyline Ventures
  • Venture Investor
    SR One

By posting a comment, you agree to our terms and conditions.